ReachRxResearch
Home
Research
Sign Up
Study limitation
Back to Research Hub
  1. Home
  2. Research Hub
  3. Study limitation

Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials

Study limitation reported by the research below: “Trial was industry-funded by Novartis, which should be considered when interpreting reported outcomes.”

Papers